glp 1 drugs kidney disease Real-World Evidence for GLP-1 Receptor Agonists Across the CKD Spectrum – AJKD Blog Kidney Outcomes With Glucagon-Like Peptide-1
Description
No one should feel alone navigating changes in their body or sex life while on these medications
It did not increase the risk of nonfatal myocardial infarction, cardiovascular death, nonfatal stroke, or hospitalization for heart failure compared with placebo
There is a big role for health tech in facilitating this transition
doi: 10.1074/jbc.M307612200 [DOI] [PubMed] [Google Scholar] 116
Diz-Chaves, Y
Ensuring continuity of treatment for current patients: Continuity is critical, especially for chronic conditions like diabetes, where consistent treatment is vital for effective disease management
